EPHA3 and head and neck cancer: As for EPHA3 (downregulated in our dataset), there is few literature data available on its expression in cervical cancer, while in other epithelial cancers (e.g., head and neck cancer [90], colorectal cancer [20], esophageal cancer [21], and clear-cell renal cell carcinoma [91]), EPHA3 has been reported to be a tumor suppressor; an inhibitor of angiogenesis, EMT, and cell migration and invasion; and a potential predictor for tumor spread, being frequently downregulated or inactivated due to promoter hypermethylation or mutation.